The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
Fangfang LiuXuemei ZhangMengyao LuChun LiuXiaodong ZhangQian ChuYuan ChenPeng ZhangPublished in: Cancer medicine (2024)
This study offers insights into genomic features of Chinese EGFR/ALK wild-type lung adenocarcinoma patients based on PD-L1 expression. Notably, Hippo pathway alterations were linked to improved immunotherapy outcomes. These findings suggest connections between the Hippo pathway and PD-L1 expression, warranting further clinical and functional investigations. The research advances our understanding of PD-L1 expression's genomic context and immunotherapy response in EGFR/ALK wild-type lung adenocarcinoma.
Keyphrases
- wild type
- small cell lung cancer
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- end stage renal disease
- copy number
- chronic kidney disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- metabolic syndrome
- patient reported outcomes
- adipose tissue
- insulin resistance
- weight loss
- patient reported